Embracing Comprehensive Restructuring for a New
Biopharmaceutical Era
Continuing the Development of MGC Pharma's Innovative Drug
Portfolio
LONDON, Feb. 13,
2024 /PRNewswire/ -- MGC Pharmaceuticals Ltd (LSE:
MXC), (OTC: MGCLF), (ASX: MXC) Rebrands as Argent BioPharma
in Strategic Transformation
Marking a significant milestone in its evolutionary journey, MGC
Pharma has officially announced its rebranding to Argent BioPharma,
pending approval from its shareholders. This rebranding is the
culmination of an extensive restructuring, incorporating
significant American capital and operational revisions. Poised for
growth, Argent BioPharma is now set to emerge as a key player in
the biopharmaceutical industry, leveraging cutting-edge
advancements in Polypharmacology and Nanotechnology. With its
presence on both the London Stock Exchange and the Australian Stock
Exchange, Argent BioPharma is well-positioned to make substantial
contributions to enhancing medical treatment accessibility.
Embracing Comprehensive Restructuring for a New
Biopharmaceutical Era
Innovating with Polypharmacology At the core of Argent
BioPharma's strategy is Polypharmacology, a revolutionary approach
that involves the creation of therapies targeting multiple
molecular targets. This strategy is instrumental in addressing
complex multifactorial diseases, setting new benchmarks in drug
development and therapeutic outcomes.
Strategic Operational Focus Argent BioPharma is strategically
focusing on generating revenue through its Investigational
Medicinal Products (IMP), available to patients in major markets
like the UK, USA, and Europe through early access schemes. This
strategy is bolstered by invaluable real-world data gathered from
these early access treatments, enhancing the safety and efficacy
profiles of their clinical trials.
The company's European research and development center is a
beacon of innovation, playing a crucial role in the entire drug
development process, from initial concept to market launch. With
two specialized manufacturing sites, Argent BioPharma adheres to
the strict EU GMP and GDP guidelines, ensuring high-quality
production standards.
Continuing the Development of MGC Pharma's Innovative Drug
Portfolio
A Future-Oriented Product Line Argent BioPharma is dedicated to
advancing its product portfolio, which focuses on immunology and
neurology, employing Polypharmacology to develop novel treatments.
Committed to introducing new treatment options every four years,
the company aims to meet urgent unmet medical needs. Its leading
products, including CannEpil® for refractory epilepsy and cerebral
palsy, CimetrA® for acute lung injury and ARDS, and CogniCann® for
dementia and Alzheimer's disease, exemplify its commitment to
innovation and patient care.
Vision, Mission, and Strategic Objectives Argent BioPharma is
driven by a vision to become a globally recognized leader in the
biopharmaceutical industry, committed to addressing unmet medical
needs through the integration of Polypharmacology and
Nanotechnology. Its mission is centered on researching and
developing innovative treatments for global health challenges,
guided by its strategic pillars of pioneering life science
innovations, ensuring global accessibility, fostering consistent
innovation, and achieving industry leadership.
Upholding Core Values and Governance Argent BioPharma not only
pledges to advance healthcare through innovative R&D but also
upholds a collaborative and ethical research culture. The company's
operations are rooted in core values of integrity, diversity,
teamwork, accountability, and excellence, all supported by a strong
foundation in Environmental, Social, and Governance principles.
As Argent BioPharma transitions from MGC Pharma, it stands ready
to lead a new era in biopharmaceuticals, promising accessible and
impactful healthcare solutions on a global scale.
Contact:
UK IR/PR Advisers
IFC Advisory
Graham Herring / Tim Metcalfe / Zach
Cohen
+44 203 934 6630
mgcpharma@investor-focus.co.uk
MGC Pharmaceuticals Ltd
Rowan Harland
Company Secretary
+61 8 6382 3390
info@mgcpharma.co.uk
Logo -
https://mma.prnewswire.com/media/1780050/mgcpharma_logo.jpg
View original
content:https://www.prnewswire.com/news-releases/mgc-pharma-rebrands-as-argent-biopharma-in-strategic-transformation-302060289.html
SOURCE MGC Pharmaceuticals Ltd